Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat

Journal of Hypertension

Volumn 14, Issue 5, 1996, Pages 601-607

  Rumble, Jonathan R ^a   Komers, Radko ^a   Cooper, Mark E ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II; Kinins; Mesenteric vessels; Nitric oxide; Vascular hypertrophy

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE METHYL ESTER; BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; KININ; NITRIC OXIDE; PERINDOPRIL; RAMIPRIL; UNCLASSIFIED DRUG; ZD 7155;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS; HYPERTROPHY; MALE; MESENTERY BLOOD VESSEL; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029973752     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199605000-00009     Document Type: Article

References (41)

1. Erdos EG: Conversion of angiotensin I to angiotensin II. Ann Rev Med 1976, 60:749-759.
2. Ignarro LJ, Buga GM, Chaudhuri G: EDRF generation and release from perfused bovine pulmonary artery and vein. Eur J Pharmacol 1990, 149:79-88.
3. Cherry PD, Furchgott RF, Zawadsky JV, Jothianandan D: Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci USA 1982, 79:2106-2110.
4. Komers R, Cooper ME: Acute renal hemodynamic effects of angiotensin converting enzyme inhibitors in diabetic hyperfiltration: the role of kinins. Am J Physiol 1995, 37:F588-F594.
5. Linz W, Scholkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989, 11:1325-1350.
6. Clozel JP, Kuhn H, Hefti F: Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989, 7:267-275.
7. Kakinuma Y, Kawamura T, Bills T, Yoshiola T, Ichikawa I, Fogo A: Blood pressure independent effect of angiotensin inhibition on vascular lesions in chronic renal failure. Kidney Int 1992, 42:46-55.
8. Powell JS, Clozel J-P, Muller RKM, Kuhn H, Hefti F, Hosang M, et al.: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989, 245:186-188.
9. Farhy RD, Carretero OA, Ho K-L, Scicli AG: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993, 72:1202-1210.
10. Cooper ME, Allen TJ, O'Brien RC, Papazoglou D, Clarke B, Jerums G, et al.: Nephropathy in a model combining genetic hypertension with experimental diabetes: enalapril versus hydralazine and metoprolol therapy. Diabetes 1990, 39:1575-1579.
11. Rumble JR, Doyle AE, Cooper ME: Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension with diabetes. Am J Hypertens 1995, 8:53-57.
12. Geisterfer AA, Peach MJ, Owens GK: Angiotensin II Induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988, 62:749-756.
13. Anderson PW, Do YS, Hsueh WA: Angiotensin II causes mesangial cell hypertrophy. Hypertension 1993, 21:29-35.
14. 2-bradykinin receptor antagonist Hoe 140 abolishes antihypertrophic effect of ramipril. Br J Pharmacol 1992, 105:771-772.
15. O'Sullivan JB, Harrap SB: Resetting blood pressure in spontaneously hypertensive rats: the role of bradykinin. Hypertension 1995, 25:162-165.
16. Unthank JL, Bohlen HG: Intestinal microvascular growth during maturation in diabetic juvenile rats. Circ Res 1988, 63:429-436.
17. Jandeleit K, Rumble J, Jackson B, Cooper ME: Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus. Clin Exp Pharmacol Physiol 1992, 19:343-347.
18. Cooper ME, Rumble J, Komers R, Du H-C, Jandeleit K, Chou ST: Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin converting enzyme inhibition. Diabetes 1994, 43:1221-1228
19. Nguyen DT, Panagiotopoulos S, Soulis T, Cooper ME, Jerums G: Aminoguanidine and methylguanidine reduces mesenteric vascular enlargement in experimental diabetes [abstract]. Diabetologia 1995, 38 (suppl 1):A255.
20. Bunag RD: Validation in awake rats of a tall-cuff method for measuring systolic pressure. J Appl Physiol 1973, 34:279-282.
21. Schmidt FH: Enzymatic determination of glucose and fructose simultaneously. Klin Wochenschr 1961, 39:1244-1247.
22. Mendelsohn FAO, Hutchinson J, Johnston CI: A review of plasma renin measurements and their clinical significance. Aust N Z J Med 1971, 1:86-93.
23. + exchange. Circ Res 1993, 73:264-268.
24. Snedecor GW, Cochran WG: Statistical Methods. 7th Edition. Ames, Iowa: Iowa State University Press; 1980:228-236.
25. Taylor PD, Wickenden AD, Mirrlees DJ, Poston L: Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin-induced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat. Br J Pharmacol 1994, 111:42-48.
26. Wu HY, Jeng YY, Yue CJ, Chyu KY, Hsueh WA, Chan TM: Endothelial-dependent vascular effects of insulin and insulin-like growth factor 1 in the perfused rat mesenteric artery and aortic ring. Diabetes 1994, 43:1027-1032.
27. Connors BA, Bohlen HG, Evan AP: Vascular endothelium and smooth muscle remodeling accompanies hypertrophy of intestinal arterioies in streptozotocin diabetic rats. Microvasc Res 1995, 49:340-349.
28. Allen TJ, Hulthen UL, Rumble J, Jasik M, Cooper ME: Diabetic vascular hypertrophy and albuminuria: role of ACE inhibition. J Diab Compl 1995, 9:318-322.
29. G-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol 1991, 103:1321-1326.
30. Daemen NJAP, Lombardi DM, Bosman FT, Schwarte SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991, 68:459-456.
31. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK: Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 1995 377:744-747.
32. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, et al.: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377:748-750.
33. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes : functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993, 265:F477-F486.
34. Vranes, D, Dilley RJ, Cooper ME: Vascular changes in the diabetic kidney: effects of ACE inhibition. J Diab Compl 1995, 9:296-300.
35. Komers R, Allen TJ, Cooper ME: Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 1994, 43:1190-1197.
36. Schricker K, Hamann M, Kaissling B, Kurtz A: Renal autacoids are involved in the stimulation of renin gene expression by low perfusion pressure. Kidney Int 1994, 46:1330-1336.
37. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G: Glomerular filtration rate in the streptozocin diabetic rat. The role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes 1990, 38:1182-1190.
38. 2 receptor antagonist [abstract]. Circulation 1992, 86 (suppl 1):226.
39. Rakugi H, Kim D-K, Krieger JE, Wang DS, Dzau VJ, Pratt RE: Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 1994, 93:339-346.
40. Bao G, Gohlke P, Quadri F, Linger T: Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992, 20:74-79.
41. Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition. Kidney Int 1993, 44:545-550.